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Fibronectin-like type II domainPhospholipase A2 receptor 1 (PLA2R) mediates collagen-dependent migration. The mechanisms by
which PLA2R interacts with collagen remain unclear. We produced HEK293 cells expressing
full-length wild-type PLA2R or a truncated PLA2R that lacks ﬁbronectin-like type II (FNII) domains
or several regions of C-type lectin-like domain (CTLD). We show that the CTLD1–2 as well as the
FNII domain of PLA2R are responsible for binding to collagen and for collagen-dependent migration.
Thus, multiple regions and domains of the extracellular portion of PLA2R participate in the respons-
es to collagen. These data suggest a potentially new mechanism for PLA2R-mediated biological
response beyond that of a receptor for secretory PLA2.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Phospholipase A2 receptor 1 (PLA2R), a so-called M-type PLA2
receptor, is a type I transmembrane glycoprotein with a molecular
mass of 180kDa. It is composed of an extracellular portion consist-
ing of an N-terminal cysteine-rich domain, a ﬁbronectin-like type II
(FNII) domain, a tandem repeat of 8 C-type lectin-like domains
(CTLD) as well as a short intracellular C-terminal region [1–4].
PLA2R is a member of the mannose receptor family that includes
the macrophage mannose receptor, Endo 180 and DEC-205 [4].
Mouse PLA2R has a high afﬁnity to mouse secretory (s) PLA2-IB,
-IIA, -IIE, -IIF and -X [2,3,5].
Previous reports raised the possibility that PLA2R may be direct-
ly linked to a signal transduction system that mediates
sPLA2s-induced biological responses independent of enzymatic
activities of sPLA2s [6–8]. However, the cytoplasmic tail of PLA2R
does not seem to contain any speciﬁc signaling motifs other thaninternalization motif on the basis of its sequence [1–4,9]. We have
recently shown that extracellular portion of PLA2R interacts with
that of integrin b1 through collagen type I and that PLA2R induces
collagen-dependent migration of myoﬁbroblasts through integrin
b1-mediated intracellular signaling mechanism [10]. In addition,
Bernard and his colleagues showed that PLA2R induces cancer cell
death through JAK2-mediated mechanism [11]. Thus, PLA2R seems
to have multiple functions beyond a receptor for sPLA2s. However,
their precise mechanisms remain unclear.
The mannose receptor, Endo180, and PLA2R have collagen bind-
ing activity [12–17] that is mediated by the FNII domain. FNII
domain is the mostly highly conserved sequence in the mannose
receptor family [4]. Recent reports showed that CTLD1–2 also plays
a role in binding to collagen and the internalization of collagen in
addition to the FNII domain in the mannose receptor and Endo180
[13,15–17]. Previous reports showed that mannose receptor and
Endo180 had distinct speciﬁcity for certain types of collagen
[14,18] and that CTLDs modulated the selectivity of binding for col-
lagen [14–17]. However, role of CTLDs and the selectivity of colla-
gen types in the interaction between PLA2R and collagen remain to
be determined. Here, we used cells expressing modiﬁed versions of
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Fig. 1. Schematic representation of full-length wild-type and mutant PLA2Rs and
Western blot analysis of their expression in HEK293 cells. (A) Four mutants of the
PLA2R are designated, i.e.,DFNII that lacks the ﬁbronectin-like type II (FNII) domain,
DCTLD1–2 that lacks the C-type lectin-like domain (CTLD) 1 and 2, DCTLD3–5 that
is missing CTLD3–5, and DCTLD2–8 in which CTLD2–8 was deleted. The amino-
terminal signal sequence is not shown. A myc and DDK tag were fused to the C-
terminuses of human full-length and mutant PLA2R (not shown). Cys-R, cysteine
rich domain; TM, transmembrane domain; Cyto, cytoplasmic domain. (B and C)
Western blot analysis of full-length wild-type and mutant PLA2Rs expressed in
HEK293 cells. Protein extracts from HEK293 cells were resolved by SDS–PAGE using
10% gels and were Western blotted with either anti-mouse PLA2R antibody
(TB1427) for mouse PLA2R (B) or anti-DDK antibody for human PLA2R (C).
Apparent molecular weights of full-length and mutant PLA2R are consistent with
their calculated molecular weights, indicating that all mutants were efﬁciently
translated. No protein band was detected in control mock-transfected cells.
830 S. Takahashi et al. / FEBS Letters 589 (2015) 829–835PLA2R to elucidate the role of each extracellular domain of PLA2R in
the binding and migration on collagen type I.
2. Materials and methods
2.1. Reagents
Human collagens type I and IV from placenta, human ﬁbronect-
in and vitronectin from plasma, mouse laminin, and rat tail colla-
gen I were purchased from BD Biosciences (Bedford, MD, USA).
Mouse collagen type I and IV were purchased from AbD Serotec
(Kidlington, UK) and Corning (Bedford, MD, USA), respectively.
Recombinant mouse and human secretory PLA2 type IB
(sPLA2-IB) were obtained from Life Technologies (Carlsbad, CA,
USA) and R&D Systems (Minneapolis, MN, USA), respectively. A
polyclonal antibody against the intracellular domain of mouse
PLA2R (clone TB1427) was developed in our laboratory
(Supplementary Figs. 1 and 2). Antibody against CTLD2–3 of mouse
PLA2R (clone 912F) was prepared as described in our previous
reports [10,19]. Anti-DDK antibody was from OriGene (Rockville,
MD, USA). Antibody against CTLD5–6 of human PLA2R was from
Genetex (Irvine, USA). Sodium [125I]-iodine (carrier-free,
3.7 GBq/mL) was purchased from Perkin Elmer (Boston, MA, USA).
2.2. Generation of cDNA constructs encoding PLA2R and mutant forms
Poly(A)+ RNA was puriﬁed from total RNA that was extracted
from mouse lung expressing PLA2R (RefSeq accession No.
NM_008867). Mouse PLA2R cDNA was synthesized from 1 lg of
Poly(A)+ RNA and ampliﬁed by polymerase chain reaction (PCR)
using the primers listed in Supplementary Table 1. The cDNA
was inserted into pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA,
USA). pCMV6-Entry vector with a C-terminal myc-DDK tag encod-
ing human PLA2R (RefSeq accession No. NM_007366.4) was pur-
chased from OriGene. Mouse and human PLA2R mutant were
designed to delete one of the following domain or region: the
FNII domain, CTLD1–2, CTLD3–5, or CTLD2–8 (Fig. 1A). The con-
structs encoding mutants of mouse or human PLA2R were generat-
ed by PCR using KOD DNA polymerase (TOYOBO, Tokyo, Japan),
pcDNA-mouse or human PLA2R as a template and the mutagenesis
primers listed in Supplementary Table 1. The pcDNAs of all con-
structs were transformed into Escherichia coli One Shot TOP10 cells
(Invitrogen) and puriﬁed using a QIAﬁlter Plasmid Kit (QIAGEN,
Valencia, CA, USA), after which the DNA sequences were checked
to exclude sequence errors.
2.3. Cell lines and transfection
The human embryonic kidney cell line (HEK293) (ECACC No.
EC85120602) was maintained in Dulbecco’s modiﬁed Eagle’s medi-
um (DMEM) (Life Technologies, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (Life Technologies). Lipofectamine
2000 (Life Technologies) was used to mediate transfection by using
0.8 lg of cDNA construct in vector or 0.8 lg of empty vector as
control, according to the manufacturer’s protocol. Transfected cells
were striped and plated on 10-cm dishes 24 h after transfection.
The cells were selected in G418 (1 mg/mL) and cultured.
2.4. Cell migration assay
Migration assays were performed using a modiﬁed 24-well
Boyden chamber with polycarbonate ﬁlters (pore size, 8 lm) of
which the bottom surface was pre-coated with each component
of the indicated extracellular matrix (10 lg/mL) or PBS as a vehicle
for 1 h [10]. Cells (2  105 cells) were suspended in serum-freeDMEM containing 0.5% BSA and were placed in the upper chamber.
In a separate experiment, sPLA2-IB (50 nM) or PBS as a control was
placed in the lower chamber (10 times in each experiment).
Incubation lasted 3 h at 37 C in 5% CO2. After incubation, cells
on the upper surface were removed by scraping, and cells adherent
to the bottom surface of the ﬁlter were ﬁxed in methanol and
stained with a Diff Quik kit (Sysmex, Hyogo, Japan) for counting.
The number of migrating cells was determined by counting 5 ﬁelds
randomly selected from each ﬁlter with optical microscope at a
magniﬁcation of 100. Each experiment was performed in tripli-
cate and the migration was expressed as the average number of
total cells counted per ﬁeld.
2.5. Binding and internalization assay
Human and mouse collagen I, rat tail collagen I, human and
mouse collagen IV, ﬁbronectin, vitronectin, laminin (30–100 lg),
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Fig. 2. Binding of various types of collagen and other components of the
extracellular matrix to HEK293 cells expressing full-length wild-type PLA2R.
HEK293 cells expressing full-length mouse (A) or human (B) PLA2R were incubated
for 2 h at 4 C with 10 nM 125I-labeled components of the extracellular matrix or
BSA as a control in the absence or presence of a 50-fold excess of unlabeled
component and washed with cold PBS. The radioactivity associated with cells was
counted. The radioactivity of each component bound to the cells is shown after
correcting for non-speciﬁc binding. ⁄P < 0.05. n = 10 in each experiment. Mock
indicates cells transfected with empty vector. Coll denotes collagen. NS denotes
statistically not signiﬁcant.
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HCl, pH 7.5, 0.4 mM NaCl) were labeled with 30 MBq of Na125I in
pre-coated iodination tubes (Thermo Scientiﬁc, Waltham, MA,
USA), as described in our previous reports [10,19]. For binding
assays, HEK293 cells on 24-well plates were incubated with the
indicated concentrations of 125I-labeled ligands in the absence or
presence of a 50-fold excess of unlabeled ligands for 2 h at 4 C
[10,19]. After the reaction, the cells were washed 3 times with
ice-cold PBS, and then the cell-associated radioactivity was mea-
sured with a gamma counter. The speciﬁc binding is deﬁned as
the difference between binding in the presence and absence of
the unlabeled ligand, which is the difference between the total
binding and non-speciﬁc binding. To assess the internalization of
collagen I and IV, cells were incubated for 2 h at 37 C with the
indicated concentrations of 125I-labeled ligands in the binding
medium in the absence or presence of a 50-fold excess of unlabeled
ligands, after which cells were washed with ice-cold PBS and treat-
ed for 5 min with 0.25% trypsin and 1 mM EDTA to remove the
radiolabeled ligands bound on the cell surface. The residual ligands
bound on the cell surface after trypsin–EDTA treatment were less
than 1% of those after the sham treatment. After washing with
PBS, the cell-associated radioactivity was counted.
2.6. Western blotting analysis
Immunoblotting analysis was performed to detect the protein
expression of full-length or mutant PLA2R in the transfected cells.
Protein (10 lg) from the extracts of transfected cells were separat-
ed by SDS–PAGE and transferred to a polyvinylidene diﬂuoride
membrane. The membrane was treated with blocking buffer and
then incubated over night at 4 C with either with anti-mouse
PLA2R antibody (TB1427) for mouse PLA2R or anti-DDK antibody
for human PLA2R.
2.7. Measurements of mRNA
The mRNA expression levels were quantiﬁed with a real-time
two-step reverse transcriptase polymerase chain reaction (PCR)
assay using TaqMan chemistry and with the use of a 7500
Real-Time PCR System (Applied Biosystems, Foster City,
California, USA). The primers and probes were predesigned by
TaqMan Gene Expression Assays (Applied Biosystems) listed in
the Supplementary Table 2.
2.8. Statistical analysis
Unless otherwise stated, all data are expressed as
means ± S.E.M. Statistical comparisons of responses were per-
formed using Student’s t-test. When more than two groups were
compared, one-way analysis of variance was performed followed
by a Scheffe test for post hoc comparison of group means. The
results were accepted as signiﬁcantly different when P < 0.05.
3. Results
3.1. Structures of mutant PLA2Rs and their expression in HEK293 cells
We produced stably transfected HEK293 cells expressing mouse
or human full-length wild-type PLA2R or a truncated PLA2R lacking
the FNII domain (called DFNII), CTLD1–2 (DCTLD1–2), CTLD3–5
(DCTLD3–5), or CTLD2–8 (DCTLD2–8), as shown in Fig. 1A. In the
immunoblotting experiments, apparent molecular weights of
full-length and mutant PLA2Rs were consistent with their calculat-
ed molecular weights (Fig. 1B and C). Flow cytometric analysis con-
ﬁrmed cell surface expression of mouse and human full-lengthPLA2R and PLA2RDFNII, human PLA2RDCTLD1–2, and human
PLA2RDCTLD3–5 in HEK293 cells (Supplementary Fig. 3). Cell sur-
face expression of the other mutant PLA2Rs was not examined
because antibodies recognizing them were not available. HEK293
cells expressed only faint levels of mRNA of endogenous PLA2R,
mannose receptor, and Endo180 (per GAPDH mRNA expression;
5  104, 7  106, and 1  104, respectively, at 35 PCR cycles).
After transfection with a construct encoding full-length wild-type
PLA2R of either mouse or human origin, the expression of mRNA
and cell surface protein of PLA2R increased approximately
103-fold compared with transfection with an empty vector (data
not shown). Flow cytometric analysis showed that cell surface
expression of integrin subunits b1 (CD29), a1 (CD49a) and a2
(CD49b) were similar in cells expressing mouse or human
full-length or mutant PLA2R (Supplementary Fig. 4).
3.2. Binding of collagen I and other components of the extracellular
matrix to HEK293 cells expressing full-length wild-type or mutant
PLA2R
As shown in Fig. 2, all examined components of the extracellu-
lar matrix had binding activity for HEK293 cells expressing
full-length PLA2R or cells transfected with empty vector (mock).
Human collagen I and IV had a higher binding to cells expressing
either mouse PLA2R (Fig. 2A) or human PLA2R (Fig. 2B) than mock.
Mouse collagen I showed a higher level of binding to cells express-
ing mouse PLA2R but not human PLA2R as compared with mock.
Rat tail collagen I showed similar binding to cells expressing either
mouse or human PLA2R compared with mock. Thus, binding of
832 S. Takahashi et al. / FEBS Letters 589 (2015) 829–835collagen to cells expressing PLA2R appeared to be species-speciﬁc
and dependent on the types of collagen.
Human collagen I lacked an increase in binding to cells express-
ing either PLA2RDFNII, PLA2RDCTLD1–2, or PLA2RDCTLD2–8 of
mouse or human origin compared with mock (Fig. 3A and B).
Human collagen I showed a small increase in binding to mouse
or human PLA2RDCTLD3–5 (Fig. 3A and B). These results indicated
that collagen I had no binding to PLA2RDFNII, PLA2RDCTLD1–2, and
PLA2RDCTLD2–8. Thus, CTLD1–2 as well as the FNII domain were
responsible for binding of human collagen I to mouse or human
PLA2R. CTLD3–5 may have a weak contribution to the collagen
binding.
3.3. Migratory responses to collagen I in HEK293 cells expressing
full-length or mutant PLA2R
In Boyden chamber experiments, HEK293 cells migrated on ﬁl-
ters precoated with human collagen I but not on plain membranes
(PBS coating, as a control), regardless of the expression of PLA2R
(Fig. 3C and D). Cells expressing full-length PLA2R (either mouse or
human origin) showed increased migration on ﬁlters with human
collagen I (Fig. 3C and D). Similar to binding experiments, cells
expressing PLA2RDFNII, PLA2RDCTLD1–2, or PLA2RDCTLD2–8
(either mouse or human origin) failed to show an increase in their
migratory responses to collagen I. Cells expressingmouse or human
PLA2RDCTLD3–5 had a small increase in migratory response to col-
lagen I (Fig. 3C and D). Thus, these results showed similar contribu-
tion of extracellular domains of PLA2R to collagen-dependent
migratory activity as observed in the binding study.C
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Fig. 3. Impairment of binding and migration of HEK293 cells expressing mutant PLA2R in
expressing full-length or mutant mouse (A) or human (B) PLA2R. Cells were incubated wi
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coated ﬁlter membranes in Boyden chamber experiments. ⁄P < 0.05 vs. mock in respons
DCTLD1–2, PLA2R lacking CTLD1–2; DCTLD3–5, PLA2R lacking CTLD3–5; DCTLD2–8, PLA3.4. Mouse sPLA2-IB increased the migratory and binding response to
collagen I in cells expressing mouse full-length PLA2R but not those
expressing PLA2R lacking CTLD3–5
Our previous report showed that mouse sPLA2-IB increased
migratory response to human collagen I independent of its catalyt-
ic action in cultured myoﬁbroblasts [10]. We therefore examined
whether the binding of sPLA2-IB to CTLD3–5, the putative binding
sites of PLA2R [20,21], could be responsible for the increased
collagen-dependent migratory response to sPLA2-IB. As shown in
Fig. 4A, mouse sPLA2-IB increased the collagen-dependent migrato-
ry response of HEK293 cells expressing full-length mouse PLA2R
but not those expressing mouse PLA2R lacking CTLD3–5. In con-
trast, human sPLA2-IB had no effect on the migratory response of
cells expressing full-length human PLA2R or human PLA2R lacking
CTLD3–5 (Fig. 4B). Similar effects of sPLA2-IB were obtained in
experiments characterizing its binding to collagen I (Fig. 4C and
D). Collagen I did not affect binding of mouse sPLA2-IB to mouse
PLA2R (Supplementary Fig. 5).
Next, we examined speciﬁc binding of sPLA2-IB to HEK293 cells
expressing full-length PLA2R or PLA2R lacking CTLD3–5. Speciﬁc
binding of mouse sPLA2-IB was found in cells expressing mouse
full-length PLA2R but not mouse PLA2R lacking CTLD3–5 (Fig. 5A
and B). Human sPLA2-IB had no speciﬁc binding to cells expressing
either human full-length PLA2R or human PLA2R lacking CTLD3–5
(Fig. 5C and D). These results indicated that the speciﬁc binding
of mouse sPLA2-IB to CTLD3–5 of mouse PLA2R was associated with
the mouse sPLA2-IB-induced increase in binding and migratory
response to collagen I in cells expressing mouse PLA2R.C
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S. Takahashi et al. / FEBS Letters 589 (2015) 829–835 8333.5. Internalization of collagen in HEK293 cells expressing PLA2R
A recent report showed that mouse PLA2R did not mediate inter-
nalization of rat tail collagen I [16]. In agreement with that report
[16], our experiments showed that neither mouse nor human
full-length PLA2R mediated the internalization of rat tail collagen I
(Fig. 6A and B). In contrast, mouse PLA2R internalized mouse and
human collagen I and IV (Fig. 6A and C), and human PLA2R internal-
ized human collagen I and IV (Fig. 6B and D). These results indicated
that PLA2R-mediated internalization of collagen may also be
species-speciﬁc and depend on the type of collagen.
4. Discussion
The present study showed that CTLD1–2 as well as the FNII
domain of PLA2R were responsible for binding to collagen I and
collagen-dependent migration in both mouse and human PLA2R.
CTLD3–5 may have a weak contribution to the binding and migra-
tion. On the basis of no evidence that CTLDs of PLA2R have direct
binding activity for collagen [4,14,16,17], CTLDs of PLA2R may
modulate the binding activity of the FNII domain to collagen I,
thereby explaining their involvement in collagen binding of
PLA2R. In support of this concept, previous reports showed that
the collagen binding activity of the FNII domain was modulated
by the close proximity of CLTD1–2 in the mannose receptor and
Endo180 [13,15,16]. It is suggested that the FNII domain is closely
contact with neighboring domains for stabilizing the interaction
with collagen [4,22,23].
The present study showed that mouse sPLA2-IB increased bind-
ing and migratory response to collagen I in cells expressing mouse
full-length PLA2R, whereas human sPLA2-IB did not in those
expressing human PLA2R. Moreover, the present study showed that
mouse sPLA2-IB had speciﬁc binding to CTLD3–5 of mouse
full-length PLA2R. In contrast, human sPLA2-IB had no ligand activ-
ity for human PLA2R, which are consistent with a previous report10 
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Fig. 6. Species-speciﬁcity in internalization of various types of collagen in HEK293 cells expressing PLA2R. Cell-associated radioactivity after incubation of cells with 20 nM
125I-labeled collagen I and IV for 2 h at 37 C in the absence or presence of a 50-fold excess of unlabeled collagen I and IV. Cells expressed full-length PLA2R or PLA2R lacking
the FNII domain (DFNII). The speciﬁc cell-associated radioactivity is shown after correcting for non-speciﬁc association. (A and B) Internalization of collagen I by cells
expressing mouse (A) or human (B) full-length PLA2R or PLA2RDFNII, (C and D) Internalization of collagen IV by cells expressing mouse (C) or human (D) full-length PLA2R or
PLA2RDFNII. ⁄P < 0.05 vs. mock in the respective collagen. n = 6 in each experiment. Coll indicates collagen.
834 S. Takahashi et al. / FEBS Letters 589 (2015) 829–835showing the species-speciﬁcity in the ligand afﬁnity of sPLA2 to
PLA2R [3]. These results indicated that binding of sPLA2-IB to
CTLD3–4 of PLA2R may be required for sPLA2-IB-induced increase
in binding and migratory responses to collagen I in cells expressing
full-length PLA2R. There is a possibility that the binding of sPLA2-IB
to CTLD3–5 leads to conformational changes of PLA2R facilitating
the binding of the FNII domain to collagen I. In contrast, collagen
binding to FNII domain was unlikely to affect binding of sPLA2-IB
to CTLD3–5 of PLA2R. This is compatible with the data in previous
report showing that deletion of FNII domain of PLA2R did not affect
binding of sPLA2-IB to PLA2R [2]. It remains to be determined
whether other sPLA2s, including sPLA2s-IIE, -IID, -IIF, -V, and -X,
may also have species-speciﬁcity for interaction with PLA2R. On
comparison of amino acid sequences of collagen I among human,
mouse, and rat using BLAST search, there is a few difference in
the sequence among them. In addition, there is a difference in
amino acid sequences of FNII domain and CLTDs between human
and mouse [16,21]. These species-differences in amino acid
sequences of collagen I and PLA2R may account for distinct selec-
tivity of collagen I binding to PLA2R.1 
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Fig. 7. Schematic representation of potential mechanism for the interaction
between extracellular portion of mouse PLA2R and integrin b1 through collagen.
Fibronectin-like type II domain of mouse PLA2R may be linked with integrin b1 by
mouse or human collagen I, and PLA2R may induce collagen-dependent migration
and proliferation through b1 integrin-mediated signal transduction [10]. The
binding of mouse sPLA2-IB to mouse PLA2R might modulate this interaction to
promote integrin signaling independent of catalytic activity of sPLA2-IB [10].Our previous report [10] and the present data proposed poten-
tially new mechanisms (Fig. 7) that aid our understanding of the
role of the sPLA2–PLA2R pathway in various pathological condi-
tions including inﬂammation, ﬁbrosis, and cancer. This is reminis-
cent of urokinase-type plasminogen activator receptor, a glycosyl
phosphatidylinositol-linked protein that induces cell adhesion,
migration and proliferation through its interaction with the extra-
cellular domain of integrins [24]. The modulation of the interac-
tion between PLA2R and collagen has the potential to lead to
novel therapeutic strategies for various pathological conditions
in which PLA2R plays a role. PLA2R was identiﬁed as a major anti-
gen in idiopathic membranous nephropathy [25]. However, role
of PLA2R in the genesis of membrane nephropathy remains
unclear.
In summary, PLA2R bound to collagen I, and binding of collagen
to PLA2R induced migratory responses to collagen I. The CTLD1–2
as well as the FNII domain of PLA2R were responsible for binding
to collagen I and collagen-dependent migration in both mouse
and human PLA2R. The CTLD3–5 may have a weak contribution
to the binding and migration. The interaction between extracellu-
lar portion of PLA2R and collagen was species-speciﬁc and depend-
ed on types of collagen. These data may help our understanding of
the role of PLA2R in various pathological conditions including
inﬂammation, ﬁbrosis, and cancer.Author contributions
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